1. The approach (s), which is/are currently followed to produce human monoclonal antibodies, is/are known as
A. transformation of antigen-specific B lymphocytes (EBV)
B. hybridization of 6-thioguanine-resistant human plasmacytoma with immune human lymphocytes
C. combination of EB Vand hybridoma techniques
D. all of these
2. Some cross-reactions with monoclonal antibodies (MAbs) can occur. Unexpected cross-reactions occur more frequently with
A. Ig MAbs
B. IgG
C. IgA
D. IgE
3. Preliminary clinical results with a humanized antibody against the interleukin-2 receptor have suggested the
A. absence of human immune response against murine proteins (HAMA) response
B. presence of HAMA response
C. poor recognition of immunoglobulin, Ig constant regions
D. all of the above
4. The cross-linkage of antigens by antibodies is known as
A. agglutination
B. complement fixation
C. a cross-reaction
D. all of these
5. In monoclonal antibody technology, tumor cells that can replicate endlessly are fused with mammalian cells that produce an antibody. The result of this cell fusion is a
A. hybridoma
B. myeloma
C. natural killer cell
D. lymphoblast